If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baqsimi ® (glucagon) nasal powder
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
BAQSIMI™ (glucagon) nasal powder: Contraindications
Baqsimi (glucagon nasal powder) is contraindicated in patients with pheochromocytoma, insulinoma, or known hypersensitivity to glucagon or to any of the excipients.
Baqsimi is contraindicated in people with
pheochromocytoma because of the risk of substantial increase in blood pressure
insulinoma because of the risk of hypoglycemia, and
known hypersensitivity to glucagon or to any of the excipients in Baqsimi.1
Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.1
Enclosed Prescribing Information
BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly
1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Baqsimi = Baqsimi™ (glucagon) nasal powder
Date of Last Review: November 16, 2020